Skip to main content

Random Mutagenesis of Peptide Aptamers as an Optimization Strategy for Inhibitor Screening

  • Protocol
  • First Online:
Rational Drug Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 928))

Abstract

Accumulating work over the past decade has shown that peptide aptamer screening represents a valid strategy for inhibitor identification that can be applied to a variety of different targets. Because of the screening method in cells and the highly combinatorial libraries available, this approach yields rapidly highly specific candidate inhibitors. Once a hit peptide has been identified, its interaction strength and affinity towards its target protein can be optimized even more, in order to increase its inhibition efficiency when subsequently applied in vivo. A condition to a successful optimization is that gain of inhibition strength should not result in loss of specificity.

Here we present a simple method for peptide aptamer optimization, which can be achieved by PCR-based random mutagenesis combined with a selection screen in yeast using a strong selective drug. The rationale of this approach, which has proven valid and efficient, is that stronger interaction in yeast will also lead to stronger inhibition. Our optimization method is effective, without loss of specificity, which is of a great importance for the discovery of inhibitors that target specific protein–protein interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380:548–50

    Article  PubMed  CAS  Google Scholar 

  2. Crawford M, Woodman R, Ko Ferrigno P (2003) Peptide aptamers: tools for biology and drug discovery. Brief Funct Genomic Proteomic 2:72–9

    Article  PubMed  CAS  Google Scholar 

  3. Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, Butz K (2004) Peptide aptamers: specific inhibitors of protein function. Curr Mol Med 4:529–38

    Article  PubMed  CAS  Google Scholar 

  4. Borghouts C, Kunz C, Groner B (2005) Peptide aptamers: recent developments for cancer therapy. Expert Opin Biol Ther 5:783–97

    Article  PubMed  CAS  Google Scholar 

  5. Schmidt S, Diriong S, Mery J, Fabbrizio E, Debant A (2002) Identification of the first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio. FEBS Lett 523:35–42

    Article  PubMed  CAS  Google Scholar 

  6. Bouquier N, Fromont S, Zeeh JC, Auziol C, Larrousse P, Robert B, Zeghouf M, Cherfils J, Debant A, Schmidt S (2009) Aptamer-derived peptides as potent inhibitors of the oncogenic RhoGEF Tgat. Chem Biol 16:391–400

    Article  PubMed  CAS  Google Scholar 

  7. Yoshizuka N, Moriuchi R, Mori T, Yamada K, Hasegawa S, Maeda T, Shimada T, Yamada Y, Kamihira S, Tomonaga M, Katamine S (2004) An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J Biol Chem 279:43998–4004

    Article  PubMed  CAS  Google Scholar 

  8. Cadwell RC, Joyce GF (1992) Randomization of genes by PCR mutagenesis. PCR Methods Appl 2:28–33

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to Anne Briançon-Marjollet for her contribution to the library construction. This work was supported by grants from the ANR “Physique et chimie du vivant” grant N° 06-137373. N. B. was supported by a CNRS valorization fellowship from CNRS. All authors are members of the CNRS consortium GDR2823.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne Debant .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this protocol

Cite this protocol

Bouquier, N., Fromont, S., Debant, A., Schmidt, S. (2012). Random Mutagenesis of Peptide Aptamers as an Optimization Strategy for Inhibitor Screening. In: Zheng, Y. (eds) Rational Drug Design. Methods in Molecular Biology, vol 928. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-008-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-008-3_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-007-6

  • Online ISBN: 978-1-62703-008-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics